SEC Form 4	
------------	--

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	ST/
--	--	-----

## ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

L		
	OMB Number:	3235-0287
	Estimated average burd	en
	hours per response:	0.5

1. Name and Address of Reporting Person <sup>*</sup> Gergel Ivan P. (Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH		(Middle)	2. Issuer Name and Ticker or Trading Symbol <u>NEKTAR THERAPEUTICS</u> [ NKTR ] 3. Date of Earliest Transaction (Month/Day/Year) 12/15/2015		ionship of Reporting Persor all applicable) Director Officer (give title below) SVP & Chief Medica	10% Owner Other (specify below)
(Street) SAN FRANCISCO (City)	CA (State)	94158 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	dual or Joint/Group Filing (( Form filed by One Reporti Form filed by More than C Person	ing Person

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Security					(A) or Disposed		(A) or Disposed of (D) (Instr.				,			Following Reported Transaction(s) (Instr. 4)	(I) (Instr. 4)	(
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Unit	(1)	12/15/2015		Α		12,500		(2)	12/14/2023	Common Stock	12,500	\$0.00	12,500	D			
Stock Option	\$15.55	12/15/2015		A		15,000		(3)	12/14/2023	Common Stock	15,000	\$0.00	15,000	D			

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.

2. This restricted stock unit vests over 3 years in equal quarterly installments.

3. This stock option vests in equal monthly installments over the 4-year period following the grant date.

**Remarks:** 

## Gil M. Labrucherie, Attorney-12/17/2015

\*\* Signature of Reporting Person Date

<u>in-Fact</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.